AKT1 and hepatocellular carcinoma: MiR-367-3p elevates the efficacy of sorafenib in HCC by functioning as an androgen receptor (AR) enhancer, resulting in dephosphorylation and inactivation of AKT, and ERK via altering the MDM2-AR-FKBP5-PHLPP signals (46).